Merck (MRK) Retained Earnings : $53,895 Mil (As of Dec. 2023)

View and export this data going back to 1949. Start your Free Trial

What is Merck Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Merck's retained earnings for the quarter that ended in Dec. 2023 was $53,895 Mil.

Merck's quarterly retained earnings increased from Jun. 2023 ($54,198 Mil) to Sep. 2023 ($57,082 Mil) but then declined from Sep. 2023 ($57,082 Mil) to Dec. 2023 ($53,895 Mil).

Merck's annual retained earnings increased from Dec. 2021 ($53,696 Mil) to Dec. 2022 ($61,081 Mil) but then declined from Dec. 2022 ($61,081 Mil) to Dec. 2023 ($53,895 Mil).

Merck Retained Earnings Historical Data

The historical data trend for Merck's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Retained Earnings Chart

Merck Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

46,602.00

47,362.00

53,696.00

61,081.00

53,895.00

Merck Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Retained Earnings	Get a 7-Day Free Trial															61,081.00	62,039.00	54,198.00	57,082.00	53,895.00

Merck Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Merck (NYSE:MRK) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Merck (MRK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (NYSE:MRK) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

MRK:Peru MRK:Mexico 1MRKX:Italy 6MKd:UK 0QAH:UK 6MK:Germany 6MK:Germany 6MK:Germany 6MK:Germany MRK:Chile MRCK34:Brazil MRK:Austria MRK:Argentina

Address

126 East Lincoln Avenue, Rahway, NJ, USA, 07065

Website

https://www.merck.com

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Executives

Johannes Jacobus Oosthuizen	officer: SVP, U.S. Market	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Richard R. Deluca	officer: EVP&Pres, Merck Animal Heallth	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Steven Mizell	officer: EVP,Human Resources	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Joseph Romanelli	officer: President, Human Health Int?l	126 EAST LINCOLN AVENUE, RAHWAY NJ 07065
Rita A Karachun	officer: Sr. VP Fince-Global Controller	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Jennifer Zachary	officer: EVP, General Counsel	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
David Michael Williams	officer: EVP,Chief Info&Digital Officer	MERCK & CO., INC., 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Robert M Davis	officer: Evp, Global Svcs & CFO	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Sanat Chattopadhyay	officer: Exe V-P & Pres. MMD	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kenneth C Frazier	officer: Chairman, President & CEO	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Chirfi Guindo	officer: Chief Marketing Officer	C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Baker Douglas M Jr	director	370 WBASHA ST NORTH, ST PAUL MN 55102
Arpa Garay	officer: SVP Human Health Global Mktg.	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Caroline Litchfield	officer: EVP & CFO	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Julie L. Gerberding	officer: EVP Strat Comm, GI Pub Policy	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033